{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'alkaline phosphatase, bilirubin) and perform', 'For bilirubin or INR criteria:', 'liver event follow up assessments within 24', 'hrs', 'Anti-nuclear antibody, anti-smooth muscle', 'antibody, Type 1 anti-liver kidney microsomal', 'Monitor participants twice weekly until liver', 'antibodies, and quantitative total immunoglobulin', 'chemistries resolve, stabilize or return to', 'G (lgG or gamma globulins).', 'within baseline', 'Serum acetaminophen adduct HPLC assay', 'A specialist or hepatology consultation is', '(quantifies potential acetaminophen contribution to', 'recommended', 'liver injury in participants with definite or likely', 'For All other criteria:', 'acetaminophen use in the preceding week', '[James, 2009]) Note: not required in China', 'Repeat liver chemistries (include ALT, AST,', 'alkaline phosphatase, bilirubin) and perform', 'Liver imaging (ultrasound, magnetic resonance, or', 'liver event follow up assessments within 24-', 'computerized tomography) and /or liver biopsy to', '72 hrs', 'evaluate liver disease complete Liver Imaging', 'and/or Liver Biopsy CRF forms.', 'Monitor participants weekly until liver', 'chemistries resolve, stabilize or return to', 'within baseline', '1.', 'Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue study treatment for that participant if ALT >3xULN and bilirubin >2xULN.', 'Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary', 'bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.', '2.', 'All events of ALT >3xULN and bilirubin 2xULN (>35% direct bilirubin) or ALT >3xULN and INR>1.5, if INR', \"measured which may indicate severe liver injury (possible 'Hy's Law'), must be reported as an SAE (excluding\", 'studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated', 'will not apply to participants receiving anticoagulants', '3.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or', 'eosinophilia)', '4.', 'Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (lgM); Hepatitis C', 'RNA; Cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain', 'heterophile antibody or monospot testing); Hepatitis E IgM antibody', '5.', 'If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA virus', '(where needed) [Le Gal, 2005].', '6.', 'Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to', \"blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the participant's best\", 'approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in', 'the time period indicated above, do not obtain a PK sample.', '127']['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'Phase I/II Oncology liver chemistry increased monitoring criteria with continued', 'therapy', 'Liver Chemistry Increased Monitoring Criteria - Liver Monitoring Event', 'Criteria', 'Actions', 'ALT >3xULN but <5xULN and', 'Notify the GSK medical monitor within 24 hours of', 'learning of the abnormality to discuss participant', 'bilirubin <2xULN, without symptoms believed', 'safety.', 'to be related to liver injury or hypersensitivity', 'and who can be monitored weekly for 4 weeks', 'Participant can continue study treatment', 'Participant must return weekly for repeat liver', 'chemistries (ALT, AST, alkaline phosphatase,', 'bilirubin) until they resolve, stabilize or return to', 'within baseline', 'If at any time participant meets the liver chemistry', 'stopping criteria, proceed as described above', 'If, after 4 weeks of monitoring, ALT <3xULN and', 'bilirubin <2xULN, monitor participants twice monthly', 'until liver chemistries normalize or return to within', 'baseline.', '12.7.1.', 'Liver Safety Drug Restart or Re-Challenge Guidelines', 'If participant meets liver chemistry stopping criteria do not restart/re-challenge', 'participant with study treatment unless all the following conditions are met:', 'GSK Medical Governance approval is granted (as described below)', 'IRB/IEC approval is obtained, if required', 'Separate consent for treatment restart/re-challenge is signed by the participant', 'If GSK Medical Governance approval to restart/re-challenge participant with study', 'treatment is not granted, then participant must permanently discontinue study treatment', 'and may continue in the study for protocol-specified follow up assessments.', '12.7.1.1. Re-challenge Following Liver Stopping Events that are Possibly', 'Related to Study Treatment', 'Re-challenge refers to resuming study treatment following drug-induced liver injury', '(DILI). Because of the risks associated with re-challenge after DILI, this should only be', 'considered for a participant for whom there is compelling evidence of benefit from a', 'critical or life-saving medicine, there is no alternative approved medicine available, and', 'a', 'benefit: risk assessment of re-challenge is considered to be favorable.', 'Following DILI, drug re-challenge is associated with a 13% mortality across all drugs in', 'prospective studies [Andrade, 2009]. Clinical outcomes vary by drug with nearly 50%', '128']\n\n###\n\n", "completion": "END"}